Impact of the Occlusion Duration on the Performance of J-CTO Score in Predicting Failure of Percutaneous Coronary Intervention for Chronic Total Occlusion.

OBJECTIVES: The present study examined the association between Multicenter CTO Registry in Japan (J-CTO) score in predicting failure of percutaneous coronary intervention (PCI) correlating with the estimated duration of chronic total occlusion (CTO). BACKGROUND: The J-CTO score does not incorporate estimated duration of the occlusion. METHODS: This was an observational retrospective study that involved all consecutive procedures performed at a single tertiary-care cardiology center between January 2009 and December 2014. RESULTS: A total of 174 patients, median age 59.5 years (interquartile range [IQR], 53-65 years), undergoing CTO-PCI were included. The median estimated occlusion duration was 7.5 months (IQR, 4.0-12.0 months). The lesions were classified as easy (score = 0), intermediate (score = 1), difficult (score = 2), and very difficult (score ≥3) in 51.1%, 33.9%, 9.2%, and 5.7% of the patients, respectively. Failure rate significantly increased with higher J-CTO score (7.9%, 20.3%, 50.0%, and 70.0% in groups with J-CTO scores of 0, 1, 2, and ≥3, respectively; P<.001). There was no significant difference in success rate according to estimated duration of occlusion (P=.63). Indeed, J-CTO score predicted failure of CTO-PCI independently of the estimated occlusion duration (P=.24). Areas under receiver-operating characteristic curves were computed and it was observed that for each occlusion time period, the discriminatory capacity of the J-CTO score in predicting CTO-PCI failure was good, with a C-statistic >0.70. CONCLUSION: The estimated duration of occlusion had no influence on the J-CTO score performance in predicting failure of PCI in CTO lesions. The probability of failure was mainly determined by grade of lesion complexity.

Impact of the occlusion duration on the performance of j-cto score in predicting failure of percutaneous coronary intervention for chronic total occlusion

Abstract: Objectives. The present study examined the association between Multicenter CTO Registry in Japan (J-CTO) score in predicting failure of percutaneous coronary intervention (PCI) correlating with the estimated duration of chronic total occlusion (CTO). Background. The J-CTO score does not incorporate estimated duration of the occlusion. Methods. This was an observational retrospective study that involved all consecutive procedures performed at a single tertiary-care cardiology center between January 2009 and December 2014. Results. A total of 174 patients, median age 59.5 years (interquartile range [IQR], 53-65 years), undergoing CTO-PCI were included. The median estimated occlusion duration was 7.5 months (IQR, 4.0-12.0 months). The lesions were classified as easy (score = 0), intermediate (score = 1), difficult (score = 2), and very difficult (score ≥3) in 51.1%, 33.9%, 9.2%, and 5.7% of the patients, respectively. Failure rate significantly increased with higher J-CTO score (7.9%, 20.3%, 50.0%, and 70.0% in groups with J-CTO scores of 0, 1, 2, and ≥3, respectively; P0.70...

[Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound]. / Asociación entre la concentración plasmática de proteína C reactiva y el volumen de hiperplasia neointimal en pacientes tratados con implante de stent liberador de zotarolimus. Análisis volumétrico con ecografía intracoronaria tridimensional.

INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP) is an inflammatory marker that predicts cardiac events in patients with coronary syndromes. However, data on the relationship between the CRP level and in-stent restenosis are contradictory. The objective of this study was to investigate the relationship between the basal CRP level and the neointimal hyperplasia volume measured by intracoronary ultrasound 4 months after implantation of a zotarolimus-eluting stent. METHODS: The study included 40 consecutive patients who underwent zotarolimus-eluting stent implantation. Patients were divided into quartiles according to their preprocedural CRP level. Intracoronary ultrasound was performed after stent implantation and at 4 months, and the neointimal hyperplasia volume was determined using Simpson's rule. Correlation and linear regression analyses were used to evaluate the relationships between variables. Multivariate analysis was used to identify variables that were independently related to neointimal hyperplasia volume. RESULTS: The patients' mean age was 58 (8) years, 55% were male, and 40% had diabetes mellitus. There was no difference in baseline characteristics between the quartiles. The hyperplasia volumes were 4.8 (4.2) microl and 15.8 (10.0) microl in the first and fourth quartiles, respectively (P< .001). There was a significant positive correlation between the CRP level and neointimal hyperplasia volume (r = 0.64, P=.0001). The CRP level, the postimplantation lumen volume, and the final deployment pressure were all independent predictors of neointimal hyperplasia. CONCLUSIONS: In this study, an independent correlation was observed between the CRP level before zotarolimus-eluting stent implantation and the neointimal hyperplasia volume at 4-month follow-up.

asociación entre la concentración de plasmática de proteina C reactiva y el volumen de hiperplasia neointimal en pacientes tratados con implante de stent liberador de zotarolimus. Análisis volumétrico con ecografía intracoronariana tridimensional / Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound

INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP) is an inflammatory marker that predicts cardiac events in patients with coronary syndromes. However, data on the relationship between the CRP level and in-stent restenosis are contradictory. The objective of this study was to investigate the relationship between the basal CRP level and the neointimal hyperplasia volume measured by intracoronary ultrasound 4 months after implantation of a zotarolimus-eluting stent. METHODS: The study included 40 consecutive patients who underwent zotarolimus-eluting stent implantation. Patients were divided into quartiles according to their preprocedural CRP level. Intracoronary ultrasound was performed after stent implantation and at 4 months, and the neointimal hyperplasia volume was determined using Simpson's rule. Correlation and linear regression analyses were used to evaluate the relationships between variables. Multivariate analysis was used to identify variables that were independently related to neointimal hyperplasia volume. RESULTS: The patients' mean age was 58 (8) years, 55% were male, and 40% had diabetes mellitus. There was no difference in baseline characteristics between the quartiles. The hyperplasia volumes were 4.8 (4.2) microl and 15.8 (10.0) microl in the first and fourth quartiles, respectively (P< .001). There was a significant positive correlation between the CRP level and neointimal hyperplasia volume (r = 0.64, P=.0001). The CRP level, the postimplantation lumen volume, and the final deployment pressure were all independent predictors of neointimal hyperplasia. CONCLUSIONS: In this study, an independent correlation was observed between the CRP level before zotarolimus-eluting stent implantation and the neointimal hyperplasia volume at 4-month follow-up.

Asociación entre la concentración plasmática de proteína C reactiva y el volumen de hiperplasia neointimal en pacientes tratados con implante de stent liberador de zotarolimus. Análisis volumétrico con ecografía intracoronaria tridimensional / Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound

Introducción y objetivos. La proteína C reactiva (PCR) es un marcador inflamatorio predictor de eventos cardiacos en los síndromes coronarios; sin embargo, existe evidencia contradictoria sobre su relación con la reestenosis intra-stent. El objetivo es evaluar la asociación entre la concentración sérica de PCR basal y el volumen de hiperplasia neointimal por ecografía intracoronaria a los 4 meses tras el implante de stents con zotarolimus. Métodos. Se incluyó a 40 pacientes tratados consecutivamente con stent liberador de zotarolimus. Se determinó el valor de PCR antes del procedimiento y de acuerdo con éste se agrupó a la población en cuartiles. Se realizó ecografía intracoronaria tras el implante y a los 4 meses, evaluando el volumen de hiperplasia neointimal por la fórmula de Simpson. Para relacionar las variables se utilizaron análisis de correlación y regresión lineal. Se realizó un análisis de regresión múltiple de las variables relacionadas de forma independiente con el volumen neointimal. Resultados. La edad media fue 58 ± 8 años, el 55% eran varones y el 40% tenía diabetes, sin diferencias en las características basales entre los grupos. El volumen de hiperplasia fue 4,8 ± 4,2 µl y 15,8 ± 10 µl para el primer y el cuarto cuartil respectivamente (p < 0,001). Existió correlación positiva entre la PCR y el volumen neointimal (r = 0,64; p = 0,0001). La PCR, el volumen luminal postimplante y la presión de liberación fueron predictores independientes de hiperplasia neointimal. Conclusiones. En este estudio observamos que el valor de la PCR antes del implante de stent con zotarolimus se correlacionó de forma independiente con el volumen de hiperplasia neointimal a los 4 meses de seguimiento (AU)

Introduction and objectives. C-reactive protein (CRP) is an inflammatory marker that predicts cardiac events in patients with coronary syndromes. However, data on the relationship between the CRP level and in-stent restenosis are contradictory. The objective of this study was to investigate the relationship between the basal CRP level and the neointimal hyperplasia volume measured by intracoronary ultrasound 4 months after implantation of a zotarolimus-eluting stent. Methods. The study included 40 consecutive patients who underwent zotarolimus-eluting stent implantation. Patients were divided into quartiles according to their preprocedural CRP level. Intracoronary ultrasound was performed after stent implantation and at 4 months, and the neointimal hyperplasia volume was determined using Simpson's rule. Correlation and linear regression analyses were used to evaluate the relationships between variables. Multivariate analysis was used to identify variables that were independently related to neointimal hyperplasia volume. Results. The patients' mean age was 58 (8) years, 55% were male, and 40% had diabetes mellitus. There was no difference in baseline characteristics between the quartiles. The hyperplasia volumes were 4.8 (4.2) µl and 15.8 (10.0) µl in the first and fourth quartiles, respectively (P<.001). There was a significant positive correlation between the CRP level and neointimal hyperplasia volume (r = 0.64, P=.0001). The CRP level, the postimplantation lumen volume, and the final deployment pressure were all independent predictors of neointimal hyperplasia. Conclusions. In this study, an independent correlation was observed between the CRP level before zotarolimus-eluting stent implantation and the neointimal hyperplasia volume at 4-month follow-up (AU)

Fechamento percutâneo da comunicaçäo interatrial. Papel da ecocardiografia / Percutaneous closure of atrial septal defects. The role of transesophageal echocardiography

Objetivo - Demonstrar o papel da ecocardiografia no tratamento percutâneo da comunicação interatial (CIA) através do dispositivo de Amplatzer. Métodos - A seleção dos pacientes para implante foi realizada através da ecocardiografia transesofágica (ETE). A ETE também foi utilizada para monitorização do procedimento, auxiliando na escolha do diâmetro da prótese, verificando o posicionamento do dispositivo e analisando o resultado imediato. Durante o seguimento foram avaliadas posição da prótese, presença de shunt residual (SR) e dimensões das cavidades direitas. Resultados - Dos 55 pacientes estudados, 22 (40 por cento) foram selecionados para o implante. Treze sumeteram-se ao tratamento, 8 estão aguardando o procedimento e 1 preferiu o tratamento cirúrgico convencional. Houve sucesso em todos, em complicações devido a adequada seleção dos casos. Seis pacientes apresentaram SR imediato, com desaparecimento espontâneo em 3, em um período de até 3 meses de seguimento (SR=23 por cento). O diâmetro diastólico ventricular direito regrediu significativamente, passando de 27mm (média) para 24mm e 20mm, respectivamente, 1 e 3 meses após o procedimento (p<0,0076). Conclusão - Auxiliado pela ecocardiografia o tratamento da CIA por via pericutânea pôde ser realizado de forma segura e eficaz.

Valvuloplastia mitral percutánea con catéter-balón en pacientes portadores de comisurotomía quirúrgica previa: resultados inmediatos y seguimiento a largo plazo / Catheter balloon percutaneous mitral valvoplasty in patients previously submitted to surgical commisurotomy: results and follow up

La comisurotomía quirúrgica era, hasta hace pocos años el tratamiento de elección solución para la estenosis mitral reumática severa y sintomático. Una vez operados, los pacientes que sufrían reestenosis, debían ser reintervenidos. La valvuloplastia mitral percutánea (VMP) fué introducida en 1984 por K. Inoue como una alternativa no quirúrgica para el tratamiento de estos pacientes. Entre agosto de 1987 y agosto de 1994 fueron realizadas en nuestro Instituto 560 VMP, de la cuales 40 (80 por ciento) fueron en pacientes que habían sido previamente comisurotomizados.En 32 de ellos utilizamos la técnica de doble balón y en los 8 restantes la técnica de Inoue. Presentamos las características clínicas, ecocardiográficas y hemodinámicas de la muestra así como su comparación con las de la población general de valvuloplastias mitrales. La tasa de suceso de procedimiento fue de 97,5 por ciento. La media del área valvar (por eco-doppler) pasó de 1,03 a 2,05 cm². El gradiente transvalvular mitral disminuyó de 19 a 6 mmHg. Antes del procedimiento ningún paciente se encontraba en clase funcional (CF) I de la NYHA, 13 se presentaban en CF II, 22 en CF III y 5 en CF IV. Después de la VMP 22 pasaron a CF I, 13 a CF II, 2 persistieron en CF III, y ninguno en CF IV. De las complicaciones destacamos que dos pacientes (5 por ciento) requirieron transfusión sanguínea, uno (2,5 por ciento) sufrió fibrilación ventricular, y otro (2,5 por ciento) embolia aérea coronaria. Tres pacientes (7,5 por ciento) fueron mandados para cirugía de urgencia: dos por insuficiencia mitral severa y otro por insuceso de la punción transeptal. En un paciente (2,5 por ciento) se detectó comunicación interauricular residual. No hubo necesidad de enviar pacientes para cirugía de emergencia. No hubo óbitos. Fue realizado un seguimiento promedio de 1,9 años en 78,3 por ciento de los pacientes, donde se observa que la media del área valvar y del gradiente medio por eco-doppler no muestran alteraciones significativas con respecto a las obtenidas post-VMP inmediatas. Concluimos que la valvuloplastia mitral percutánea es una alternativa válida para los paciente que habiendo sido comisurotomizados previamente sufrieron reestenosis. Posee una alta tasa de suceso, un bajo índice de complicaciones, la durabilidad del tratamiento está comprobada y por otro lado aleja la necesidad de una reintervención quirúrgica